Early Results of Simultaneous Integrated Boost Volumetric Modulated arc Therapy (SIB-VMAT) Combined with Temozolomide in the Postoperative Treatment of Grade 4 glioblastoma
Introduction. Glioblastoma refers to a neuroepithelial malignant brain tumor with an aggressive course and extremely unfavorable prognosis. The median overall survival comprises 14.6 months. Standard treatment demonstrates relatively poor efficiency due to high recurrence rate associated with the hi...
Saved in:
| Main Authors: | Y. O. Nikulshina, A. N. Redkin, A. V. Perova |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Bashkir State Medical University
2024-07-01
|
| Series: | Креативная хирургия и онкология |
| Subjects: | |
| Online Access: | https://www.surgonco.ru/jour/article/view/951 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Kalata B1 Enhances Temozolomide Toxicity to Glioblastoma Cells
by: Samantha L. Gerlach, et al.
Published: (2024-09-01) -
Phase II trial of upfront bevacizumab and temozolomide for unresectable or multifocal glioblastoma
by: Emil Lou, et al.
Published: (2013-04-01) -
Glioblastoma multiforme: an updated overview of temozolomide resistance mechanisms and strategies to overcome resistance
by: Jianlin Pu, et al.
Published: (2025-05-01) -
Feasibility of simultaneous integrated boost for high-dose treatment of high-risk prostate cancer
by: E. S. Sukhikh, et al.
Published: (2023-06-01) -
A dosimetric comparison of non-coplanar volumetric modulated arc therapy and non-coplanar fixed field intensity modulated radiation therapy in hippocampus-avoidance whole-brain radiation therapy with a simultaneous integrated boost for brain metastases
by: Huaqu Zeng, et al.
Published: (2025-01-01)